首页> 外文期刊>Theranostics >Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets
【24h】

Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

机译:大肠腺瘤的功能基因组mRNA分析:鉴定和体内验证CD44和剪接变异CD44v6作为分子成像目标。

获取原文
           

摘要

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. High adenoma miss rates, especially seen in high-risk patients, demand for better endoscopic detection. By fluorescently 'highlighting' specific molecular characteristics, endoscopic molecular imaging has great potential to fulfill this need. To implement this technique effectively, target proteins that distinguish adenomas from normal tissue must be identified. In this study we applied in silico Functional Genomic mRNA (FGmRNA) profiling, which is a recently developed method that results in an enhanced view on the downstream effects of genomic alterations occurring in adenomas on gene expression levels. FGmRNA profiles of sporadic adenomas were compared to normal colon tissue to identify overexpressed genes. We validated the protein expression of the top identified genes, AXIN2, CEMIP, CD44 and JUN , in sporadic adenoma patient samples via immunohistochemistry (IHC). CD44 was identified as the most attractive target protein for imaging purposes and we proved its relevance in high-risk patients by demonstrating CD44 protein overexpression in Lynch lesions. Subsequently, we show that the epithelial splice variant CD44V6 is highly overexpressed in our patient samples and we demonstrated the feasibility of visualizing adenomas in Apc Min/+ mice in vivo by using a fluorescently labeled CD44v6 targeting peptide. In conclusion, via in silico functional genomics and ex vivo protein validation, this study identified CD44 as an attractive molecular target for both sporadic and high-risk Lynch adenomas, and demonstrates the in vivo applicability of a small peptide drug directed against splice variant CD44v6 for adenoma imaging.
机译:结直肠癌(CRC)是世界范围内与癌症相关的死亡的第三大主要原因。高腺瘤漏诊率,尤其是在高危患者中,要求更好的内窥镜检查。通过荧光“突出”特定分子特征,内窥镜分子成像具有满足这一需求的巨大潜力。为了有效地实施该技术,必须识别可将腺瘤与正常组织区分开的靶蛋白。在这项研究中,我们应用了计算机模拟功能基因组mRNA(FGmRNA)分析,这是一种最近开发的方法,可增强对腺瘤中基因组改变对基因表达水平的下游影响的增强见解。将散发性腺瘤的FGmRNA图谱与正常结肠组织进行比较,以鉴定过度表达的基因。我们通过免疫组织化学(IHC)验证了散发性腺瘤患者样品中最先鉴定的基因AXIN2,CEMIP,CD44和JUN的蛋白质表达。 CD44被认为是用于成像的最有吸引力的靶蛋白,并且我们通过证明Lynch病变中CD44蛋白的过度表达证明了CD44在高危患者中的相关性。随后,我们显示了上皮剪接变体CD44V6在我们的患者样品中高度过表达,并且我们证明了使用荧光标记的CD44v6靶向肽在体内可视化Apc Min / + 小鼠腺瘤的可行性。总之,通过计算机功能基因组学和离体蛋白质验证,该研究确定CD44是散发性和高风险Lynch腺瘤的有吸引力的分子靶标,并证明了针对剪接变体CD44v6的小肽药物在体内的适用性腺瘤成像。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号